Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof-Of-Concept Study.

Journal: Alimentary pharmacology & therapeutics
Published Date:

Abstract

BACKGROUND AND AIMS: Human breath contains numerous volatile organic compounds (VOCs) produced by physiological and metabolic processes or perturbed in pathological states. Electronic nose (eNose) technology has been extensively validated as a non-invasive diagnostic tool for respiratory disease. Using eNose-derived exhaled breath signals, we investigated whether it could discriminate patients with metabolic dysfunction-associated steatotic liver disease (MASLD) from healthy volunteers and identify patients at high risk of disease progression.

Authors

  • R Sinha
    Hepatology Laboratory and Centre of Liver and Digestive Diseases, Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, UK.
  • S L Gillespie
    Hepatology Laboratory and Centre of Liver and Digestive Diseases, Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, UK.
  • P Brinkman
    The Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • P Bassett
    Statistical Consultancy, Hemel Hempstead, UK.
  • K A Lockman
    Edinburgh Centre for Endocrinology and Diabetes, Royal Infirmary of Edinburgh and the University of Edinburgh, Edinburgh, UK.
  • A J Jaap
    Edinburgh Centre for Endocrinology and Diabetes, Royal Infirmary of Edinburgh and the University of Edinburgh, Edinburgh, UK.
  • J A Fallowfield
    Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.
  • P C Hayes
    Hepatology Laboratory and Centre of Liver and Digestive Diseases, Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, UK.
  • J N Plevris
    Hepatology Laboratory and Centre of Liver and Digestive Diseases, Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, UK.